Publication
Survival benchmarking of talazoparib plus enzalutamide in homologous recombination repair-deficient metastatic castration-resistant prostate cancer: a reconstructed individual patient data analysis.
Hiroki Tanaka, Hiroshi Fukushima, Shigehiro Tsukahara, Masaki Shiota, Soichiro Yoshida, Yasuhisa Fujii
Japanese journal of clinical oncologySep 16, 2026PMID 42747074doi:10.1093/jjco/hyag152 Journal ArticlepubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 17, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260917-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Homologous recombination repair (HRR) alterations define a heterogeneous subgroup of metastatic castration-resistant prostate cancer. TALAPRO-2 established randomized benefit of talazoparib plus enzalutamide within HRR-deficient disease, but it did not determine whether treated HRR-deficient…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMalignant Prostate Neoplasmdictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available
No curated evidence item cites this publication.